BioRestorative Therapies, Inc.
BRTX
$1.79
$0.0553.17%
| Weiss Ratings | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.31 | |||
| Price History | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.24% | |||
| 30-Day Total Return | 17.76% | |||
| 60-Day Total Return | -0.56% | |||
| 90-Day Total Return | 16.99% | |||
| Year to Date Total Return | 20.13% | |||
| 1-Year Total Return | 36.12% | |||
| 2-Year Total Return | -51.09% | |||
| 3-Year Total Return | -68.09% | |||
| 5-Year Total Return | 347.50% | |||
| 52-Week High % Change | -31.96% | |||
| 52-Week Low % Change | 68.45% | |||
| Price | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.55 | |||
| 52-Week Low Price | $1.03 | |||
| 52-Week Low Price (Date) | Jun 10, 2024 | |||
| 52-Week High Price (Date) | Jan 29, 2025 | |||
| Valuation | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 13.02M | |||
| Enterprise Value | 2.30M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.17 | |||
| Earnings Per Share Growth | -66.59% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 35.19 | |||
| Price/Book (Q) | 1.41 | |||
| Enterprise Value/Revenue (TTM) | 5.74 | |||
| Price | $1.79 | |||
| Enterprise Value/EBITDA (TTM) | -0.20 | |||
| Enterprise Value/EBIT | -0.20 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 8.13M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 631 760 8100 | |||
| Address | 40 Marcus Drive Melville, NY 11747 | |||
| Website | www.biorestorative.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,881.59% | |||
| Profit Margin | -2,239.25% | |||
| Management Effectiveness | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -58.03% | |||
| Return on Equity | -- | |||
| Income Statement | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 401.00K | |||
| Total Revenue (TTM) | 401.00K | |||
| Revenue Per Share | $0.05 | |||
| Gross Profit (TTM) | 373.00K | |||
| EBITDA (TTM) | -11.37M | |||
| EBIT (TTM) | -11.56M | |||
| Net Income (TTM) | -8.98M | |||
| Net Income Avl. to Common (TTM) | -8.98M | |||
| Total Revenue Growth (Q YOY) | 124.35% | |||
| Earnings Growth (Q YOY) | 28.99% | |||
| EPS Diluted (TTM) | -1.17 | |||
| EPS Diluted Growth (Q YOY) | 58.90% | |||
| Balance Sheet | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 10.73M | |||
| Cash Per Share (Q) | $1.32 | |||
| Total Current Assets (Q) | 11.14M | |||
| Total Preferred Equity (Q) | 0.01 | |||
| Total Equity (Q) | 8.53M | |||
| Current Ratio (Q) | 2.973 | |||
| Book Value Per Share (Q) | $1.23 | |||
| Total Assets (Q) | 12.28M | |||
| Total Current Liabilities (Q) | 3.75M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 3.75M | |||
| Total Common Equity (Q) | 8.52M | |||
| Cash Flow | BRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 514.60K | |||
| Cash from Financing (TTM) | 7.38M | |||
| Net Change in Cash (TTM) | -336.50K | |||
| Levered Free Cash Flow (TTM) | -3.11M | |||
| Cash from Operations (TTM) | -8.23M | |||
